Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 8/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148376 | 0.87 | ALDH1A1 (0.48) | SMN1; SMN2BRD4MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL431599 | 0.84 | MTNR1A (0.60) | SMN1; SMN2BRD4MTNR1AMTNR1BHTT | |
| SCHEMBL651279 | 0.82 | S1PR5 (0.50) | SMN1; SMN2BRD4MTNR1AMTNR1BHTT | |
| SCHEMBL10148387 | 0.81 | MTNR1A (0.42) | BRD4MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL8566298 | 0.76 | MTNR1A (0.64) | SMN1; SMN2BRD4MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL8566307 | 0.76 | MTNR1A (0.64) | SMN1; SMN2BRD4MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL8566302 | 0.76 | MTNR1A (0.64) | SMN1; SMN2BRD4MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL429947 | 0.76 | S1PR5 (0.51) | SMN1; SMN2BRD4MTNR1AMTNR1BHTT | |
| SCHEMBL8295201 | 0.74 | SMN1; SMN2 (0.71) | SMN1; SMN2BRD4HTTALDH1A1 | |
| SCHEMBL429807 | 0.74 | MTNR1A (0.58) | BRD4MTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | SMN1; SMN2 3460/4885BRD4 87/4885MTNR1A 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.